P. Rae

Nilotinib in Imatinib-Resistant CML and Philadelphia Chromosome–Positive ALL

Hagop M. Kantarjian, Francis J. Giles, Lydia Wunderle et al. · New England Journal of Medicine · 2006 · 1.3K citations · Full text

Medicine, Pharmacology, Pharmacotherapy +13

A Phase I Study of Intravenous LBH589, a Novel Cinnamic Hydroxamic Acid Analogue Histone Deacetylase Inhibitor, in Patients with Refractory Hematologic Malignancies

Francis J. Giles, Thomas Fischer, Jörge E. Cortes et al. · Clinical Cancer Research · 2006 · 314 citations

Medicine, Hematology, Pharmacology +17

UGT1A1 promoter polymorphism increases risk of nilotinib-induced hyperbilirubinemia

Jonathan B. Singer, Yaping Shou, Francis J. Giles et al. · Leukemia · 2007 · 122 citations

Life Sciences, Genetics, Molecular Genetics +9

A Phase I/II Study of AMN107, a Novel Aminopyrimidine Inhibitor of Bcr-Abl, on a Continuous Daily Dosing Schedule in Adult Patients (pts) with Imatinib-Resistant Advanced Phase Chronic Myeloid Leukemia (CML) or Relapsed/Refractory Philadelphia Chromosome (Ph+) Acute Llymphocytic Leukemia (ALL).

Francis J. Giles, Hagop M. Kantarjian, Jörge E. Cortes et al. · Blood · 2004 · 33 citations

Medicine, Oncology, Pharmacology +12

AMN107, a Novel Aminopyrimidine Inhibitor of Bcr-Abl, Has Significant Activity in Imatinib-Resistant Chronic Myeloid Leukemia (CML) or Philadelphia-Chromosome Positive Acute Lymphoid Leukemia (Ph + ALL).

Hagop M. Kantarjian, O. Ottman, Jörge E. Cortes et al. · Blood · 2005 · 20 citations

Medicine, Oncology, Pharmacology +6